MX2020006430A - Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato. - Google Patents

Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.

Info

Publication number
MX2020006430A
MX2020006430A MX2020006430A MX2020006430A MX2020006430A MX 2020006430 A MX2020006430 A MX 2020006430A MX 2020006430 A MX2020006430 A MX 2020006430A MX 2020006430 A MX2020006430 A MX 2020006430A MX 2020006430 A MX2020006430 A MX 2020006430A
Authority
MX
Mexico
Prior art keywords
oligonucleotides
internucleoside linkage
phosphorodithioate internucleoside
phosphorodithioate
oligonucleotide
Prior art date
Application number
MX2020006430A
Other languages
English (en)
Inventor
Henrik Frydenlund Hansen
Konrad Bleicher
Adrian Schaeublin
Yong Wu
Joerg Duschmalé
Martina Brigitte Duschmalé
Erik Funder
Troels Koch
Meiling Li
Xi Shu
Jesper Worm
Lars Joenson
Original Assignee
Roche Innovation Ct Copenhagen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Innovation Ct Copenhagen As filed Critical Roche Innovation Ct Copenhagen As
Publication of MX2020006430A publication Critical patent/MX2020006430A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/313—Phosphorodithioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con un oligonucleótido que comprende al menos un enlace internucleosídico de fosforoditioato de fórmula (1) VER FORMULA como se define en la descripción y en la reivindicación. El oligonucleótido de la invención se puede usar como medicamento.
MX2020006430A 2017-12-22 2018-12-21 Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato. MX2020006430A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017118040 2017-12-22
EP18198479 2018-10-03
PCT/EP2018/086460 WO2019122279A1 (en) 2017-12-22 2018-12-21 Oligonucleotides comprising a phosphorodithioate internucleoside linkage

Publications (1)

Publication Number Publication Date
MX2020006430A true MX2020006430A (es) 2020-09-17

Family

ID=65011984

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006430A MX2020006430A (es) 2017-12-22 2018-12-21 Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.

Country Status (12)

Country Link
US (2) US20200339982A1 (es)
EP (2) EP3728592B1 (es)
JP (2) JP7476102B2 (es)
KR (1) KR20200104345A (es)
CN (1) CN111757936B (es)
AU (1) AU2018386524A1 (es)
BR (1) BR112020012427A8 (es)
CA (1) CA3085406A1 (es)
IL (1) IL275399A (es)
MX (1) MX2020006430A (es)
TW (1) TW201929870A (es)
WO (1) WO2019122279A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023553069A (ja) * 2020-12-08 2023-12-20 エフ． ホフマン－ラ ロシュ アーゲー ホスホロジチオエートオリゴヌクレオチドの新規合成
JP2024521897A (ja) * 2021-06-02 2024-06-04 アタランタ セラピューティクス，インコーポレーテッド 治療用オリゴヌクレオチドを中枢神経系に送達するための組成物及び方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602244A (en) * 1988-05-26 1997-02-11 Competitive Technologies, Inc. Polynucleotide phosphorodithioate compounds
IL90359A0 (en) * 1988-05-26 1989-12-15 University Patents Inc Nucleoside and polynucleotide thiophosphoramidite and phosphorodithioate compounds and their production
AU5418290A (en) * 1989-03-31 1990-11-05 University Patents Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5218088A (en) * 1989-11-02 1993-06-08 Purdue Research Foundation Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
WO1993007883A1 (en) 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
AU4089397A (en) * 1996-08-26 1998-03-19 Hybridon, Inc. Improved reagents and process for synthesis of oligonucleotides containing phosphorodithioate internucleoside linkages
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
AU9063398A (en) 1997-09-12 1999-04-05 Exiqon A/S Oligonucleotide analogues
CZ296576B6 (cs) 1999-02-12 2006-04-12 Sankyo Company Limited Nukleosidový analog a oligonukleotidový analog a farmaceutický prostredek, sonda a primer s jeho obsahem
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
US9045518B2 (en) 2002-11-18 2015-06-02 Santaris Pharma A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
KR101789603B1 (ko) 2005-11-10 2017-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
JP5342881B2 (ja) 2006-01-27 2013-11-13 アイシス ファーマシューティカルズ， インコーポレーテッド ６−修飾された二環式核酸類似体
CA2648132C (en) 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2023940B1 (en) 2006-05-05 2011-06-22 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
WO2008049085A1 (en) 2006-10-18 2008-04-24 Isis Pharmaceuticals, Inc. Antisense compounds
WO2008113832A2 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S SHORT RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF TARGET mRNA
CN101889086B (zh) 2007-05-01 2014-07-02 桑塔里斯制药公司 Tnf超家族受体的剪接转换寡聚物，以及它们治疗疾病的用途
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
CA2692579C (en) 2007-07-05 2016-05-03 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
EP2623599B1 (en) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
EP3260540A1 (en) 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
US10017764B2 (en) 2011-02-08 2018-07-10 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
ES2651514T3 (es) 2011-08-11 2018-01-26 Ionis Pharmaceuticals, Inc. Compuestos oligoméricos gapados que comprenden deoxirribonucleósidos modificados en 5 ' -en la brecha y usos de ellos
EP3453761A1 (en) 2011-08-29 2019-03-13 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
CN104136451A (zh) 2011-09-07 2014-11-05 玛瑞纳生物技术有限公司 具有构象限制的单体的核酸化合物的合成和用途
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US10077443B2 (en) 2012-11-15 2018-09-18 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
AU2014251388B2 (en) 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
ES2770667T3 (es) 2013-06-27 2020-07-02 Roche Innovation Ct Copenhagen As Oligómeros antisentido y conjugados que se dirigen a PCSK9
WO2015113922A1 (en) 2014-01-30 2015-08-06 Roche Innovation Center Copenhagen A/S Poly oligomer compound with biocleavable conjugates
US9629867B2 (en) * 2014-03-11 2017-04-25 AM Biotechnologies, Inc. Methods and compositions of improved modified siRNA
EP3020813A1 (en) * 2014-11-16 2016-05-18 Neurovision Pharma GmbH Antisense-oligonucleotides as inhibitors of TGF-R signaling
JP2017536366A (ja) * 2014-11-19 2017-12-07 ロシュ イノベーション センター コペンハーゲン エーエス Ｌｎａキラルホスホロチオエート
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
WO2016127002A1 (en) 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
WO2016172598A1 (en) 2015-04-22 2016-10-27 The Broad Institute Inc. Exosomes and uses thereof
EP3394258B1 (en) 2015-10-22 2021-09-22 Roche Innovation Center Copenhagen A/S In vitro toxicity screening assay
WO2017173034A1 (en) 2016-03-30 2017-10-05 The University Of North Carolina At Chapel Hill Biological agent-exosome compositions and uses thereof
US11105794B2 (en) 2016-06-17 2021-08-31 Hoffmann-La Roche Inc. In vitro nephrotoxicity screening assay
AU2017289204A1 (en) 2016-07-01 2019-01-17 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating HTRA1 expression
WO2018019799A2 (en) 2016-07-27 2018-02-01 F. Hoffmann-La Roche Ag Oligonucleotide synthesis
EP4035659A1 (en) 2016-11-29 2022-08-03 PureTech LYT, Inc. Exosomes for delivery of therapeutic agents
WO2019122282A1 (en) * 2017-12-22 2019-06-27 Roche Innovation Center Copenhagen A/S Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage

Also Published As

Publication number Publication date
KR20200104345A (ko) 2020-09-03
CN111757936B (zh) 2025-07-04
EP3728592C0 (en) 2024-05-29
BR112020012427A8 (pt) 2024-04-02
BR112020012427A2 (pt) 2020-11-24
EP3728592B1 (en) 2024-05-29
CN111757936A (zh) 2020-10-09
WO2019122279A1 (en) 2019-06-27
US20230002762A1 (en) 2023-01-05
JP7476102B2 (ja) 2024-04-30
AU2018386524A1 (en) 2020-07-02
TW201929870A (zh) 2019-08-01
JP2021508690A (ja) 2021-03-11
US20200339982A1 (en) 2020-10-29
CA3085406A1 (en) 2019-06-27
JP2024041886A (ja) 2024-03-27
EP4074724A1 (en) 2022-10-19
IL275399A (en) 2020-07-30
EP3728592A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
MX2020005754A (es) Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
NZ712336A (en) Complement component c5 irna compositions and methods of use thereof
PH12017500424A1 (en) Mir-29 mimics and uses thereof
MX2015008064A (es) Composiciones pesticidas y procesos relacionados con ellas.
PH12014502398A1 (en) Pesticidal compositions and processes related thereto
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
MX2017002969A (es) Composiciones detergentes que contienen un surfactante ramificado.
MX364662B (es) Óptimos loci de maíz.
MX2017007645A (es) Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas.
MX2015011897A (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX2018002090A (es) Nanoparticulas de polinucleótido para modulación de expresión génica y sus usos.
PH12015501394A1 (en) Pesticidal compositions and processes related thereto
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
WO2018146557A3 (en) Long double-stranded rna for rna interference
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
PH12016500574A1 (en) Compositions and methods for inhibiting expression of the alas1 gene
MX386861B (es) Composiciones inhibidoras de nitrificación microencapsuladas.
MX2017007460A (es) Composicion polimerica que comprende aditivos basicos, procedimiento y articulos que comprenden dicha composicion polimerica.
UY36189A (es) Composiciones y métodos para regular la expresión génica por medio de la interferencia de arn
WO2016108927A3 (en) Nitrification inhibitor compositions and methods for preparing the same
MX2021001019A (es) Oligonucleotidos que comprenden enlace internucleosidico de fosforotritioato.
MX2020006430A (es) Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato.
MX2016011413A (es) Formulaciones que comprenden xiloglucano polimérico como portador para agentes agronómicamente beneficiosos.
IN2015DN02699A (es)